Sumitomo Pharma revenue and financials
¥1,613.00Change from previous close: +2.15%Absolute change: +¥34.00
In the fiscal year ended March 2026, Sumitomo Pharma reported revenue of ¥453.29B (+13.66% year over year). Net income was ¥106.87B, a net margin of 23.6%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.66%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +352.17%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 23.6%
- FY to Mar 2025: 5.9%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Total revenue | 453,294 | 398,832 | 314,558 | 555,544 | — |
| Cost of revenue | 196,401 | 153,437 | 126,577 | 178,919 | — |
| Gross profit | 256,893 | 245,395 | 187,981 | 376,625 | — |
| Selling, general and administrative | 162,557 | 180,605 | 429,538 | 373,316 | — |
| Research and development | 43,996 | 49,865 | 112,637 | 131,858 | — |
| Operating income | 105,053 | 29,709 | -354,836 | -76,979 | — |
| EBIT | 110,536 | 31,111 | -318,837 | -44,761 | — |
| EBITDA | 110,536 | 56,673 | -281,072 | -3,498 | — |
| Interest expense | 10,192 | 13,500 | 4,277 | 3,159 | — |
| Pre-tax income | 100,344 | 17,611 | -323,114 | -47,920 | — |
| Income tax | -6,521 | -6,024 | -8,185 | 48,794 | — |
| Net income | 106,865 | 23,634 | -314,969 | -74,512 | — |
| Net income to common shareholders | 106,865 | 23,634 | -314,969 | -74,512 | — |
| Basic EPS | — | 59.49 | -792.79 | -187.55 | 141.99 |
| Diluted EPS | — | 59.49 | -792.79 | -187.55 | 141.99 |
| Average shares (basic) | — | 397 | 397 | 397 | 397 |
| Average shares (diluted) | — | 397 | 397 | 397 | 397 |